Mediators of periodontal osseous destruction and remodeling: Principles and implications for diagnosis and therapy

Journal of Periodontology

Volumn 73, Issue 11, 2002, Pages 1377-1391

  McCauley, Laurie K ^a   Nohutcu, Rahime M ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Biological markers; Bone loss diagnosis; Bone loss therapy; Bone remodeling; Bone resorption prevention and control; Osteoclasts

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CHLORTETRACYCLINE; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DEMECLOCYCLINE; DOXYCYCLINE; ESTROGEN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; METACYCLINE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; OXYTETRACYCLINE; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PLACEBO; PROSTAGLANDIN E2; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR;

BONE DESTRUCTION; BONE DISEASE; BONE REMODELING; CELL ACTIVITY; CELL DIFFERENTIATION; HUMAN; MEDIATOR; METABOLIC BONE DISEASE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PERIODONTAL DISEASE; PERIODONTICS; REVIEW; SIDE EFFECT;

ALVEOLAR BONE LOSS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; BONE REMODELING; CELL DIFFERENTIATION; CYTOKINES; DIPHOSPHONATES; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; HUMANS; INFLAMMATION MEDIATORS; OSTEOCLASTS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRACYCLINES;

EID: 0036867381     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2002.73.11.1377     Document Type: Review

References (120)

1. Corral DA, Amling M, Priemel M, et al. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci (USA) 1998;95:13835-13840.
2. Manolagas SC. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115-137.
3. Parfitt AM. Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994;55:273-286.
4. Franceschi RT. The developmental control of osteoblast-specific gene expression: Role of specific transcription factors and the extracellular matrix environment. Crit Rev Oral Biol Med 1999; 10:40-57.
5. Doherty MJ, Ashton BA, Walsh S, Beresford J, Grant ME, Canfield ME. Vascular pericytes express osteogenic potential in vitro and in vivo. J Bone Miner Res 1998;13:828-838.
6. Ducy P, Schinke T, Karsenty G. The osteoblast: A sophisticated fibroblast under central surveillance. Science 2000;289:1501-1504.
7. Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa 1. Endocr Rev 2000;21:393-411.
8. Giannobile WV. Periodontal tissue engineering by growth factors. Bone 1996;19(Suppl.):23S-37S.
9. Gadhavi A, Wilson M, Tabona P, Newman HN, Henderson B, Bennett JH. Inhibition of mitosis and Induction of apoptosis in MG63 human osteosarcoma-derived cells in vitro by surface proteins from Actinobacillus actinomycetemcomintans. Arch Oral Biol 2000;45:707-711.
10. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-1508.
11. Kong YY, Penninger JM. Molecular control of bone remodeling and osteoporosis. Exp Gerontol 2000;35: 947-956.
12. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-1514.
13. Kim N, Takami M, Rho R, Josien R, Choi Y. A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med 2002; 195:201-209.
14. Gay CV, Weber JA. Regulation of differentiated osteoclasts. Crit Rev Eukaryot Gene Expr 2000; 10:213-230.
15. Takahashi N, Udagawa N, Takami M, Suda T. Cells of bone: Osteoclast generation. In: Bilezikian JP, Raisz LG, Rodan G, eds. Principles of Bone Biology. San Diego: Academic Press; 2002:109-126.
16. Väänänen K, Zhao H. Osteoclast function: Biology and mechanisms. In: Bilezikian JP, Raisz LG, Rodan G, eds. Principles of Bone Biology. San Diego: Academic Press; 2002:127-139.
17. Horton JE, Raisz LG, Simmons HA, Oppenheim JJ, Mergenhagen SE. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science 1972;177:793-795.
18. Boch JA, Wara-Aswapati N, Auron PE. Interleukin 1 signal transduction-Current concepts and relevance to periodontitis. J Dent Res 2001;80:400-407.
19. Kornman KS, di Giovine FS. Genetic variations in cytokine expression: A risk factor for severity of adult periodontitis. Ann Periodontol 1998;3:327-338.
20. Horowitz MC, Xi Y, Wilson K, Kacena MA. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 200 1;12:9-18.
21. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: A new paradigm for,regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000;11:905-913.
22. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;10:1434-1441.
23. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002;20:795-823.
24. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397: 315-323.
25. Kostenuik P, Shalhoub V. Osteoprotegerin: A physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 2001;7:613-635.
26. Teng Y-TA, Nguyen H, Gao X, et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000;106:R59-R67.
27. Gowen M, Nedwin GE, Mundy GR. Preferential inhibition of cytokine-stimulated bone resorption by interferon gamma. J Bone Miner Res 1986;1:469-474.
28. Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. JAMA 2001;285:1415-1418.
29. McCauley LK, Rosol TJ, Stromberg PC, Capen CC. Effects of interleukin-1 alpha and cyclosporin A in vivo and in vitro on bone and lymphoid tissues in mice. Toxicol Pathol 1991;19:1-10.
30. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-1487.
31. Kraenzlin ME, Seibel MJ. Measurement of biochemical markers of bone resorption. In: Seibel MJ, Robins SP, Bilezikian JP, eds. Dynamics of Bone and Cartilage Metabolism. San Diego: Academic Press; 1999: 411-426.
32. Giannobile WV. C-telopeptide pyridinoline cross-links. Sensitive indicators of periodontal tissue destruction. Ann N Y Acad Sci 1999;878:404-412.
33. Souberbielle JC, Cormier C, Kindermans C. Bone markers in clinical practice. Curr Opin Rheumatol 1999;11:312-319.
34. Listgarten MA. Periodontal probing: What does it mean? J Clin Periodontol 1980;7:165-176.
35. Reddy MS. The use of periodontal probes and radiographs in clinical trials of diagnostic tests. Ann Periodontol 1997;2:113-122.
36. Eley BM, Cox SW. Advances in periodontal diagnosis. 2. New clinical methods of diagnosis. Br Dent J 1998;7:1-74.
37. Bartold PM, Narayanan AS. Gingival crevicular fluid: Connective tissue elements as diagnostic markers. In: Solaro B, ed. Biology of the Periodontal Connective Tissue. Carol Stream, IL: Quintessence Publishing Co.; 1998:223-239.
38. Nakashima K, Giannopoulou C, Andersen E, et al. A longitudinal study of various crevicular fluid components as markers of periodontal disease activity. J Clin Periodontol 1996;23:832-838.
39. Lamster IB. Evaluation of components of gingival crevicular fluid as diagnostic tests. Ann Periodontot 1997;2:123-137.
40. Masada MP, Persson R, Kenney JS, Lee SW, Page RJ, Allison AC. Measurement of interleukin- 1α and - 1β in gingival crevicular fluid: Implications for the pathogenesis of periodontal disease. J Periodont Res 1990;25:156-163.
41. Mogi M, Otogoto J, Ota N, Inagaki H, Minami M, Kojima K. Interleukin-1 beta, interleukin-6, beta 2- microglobulin, and transforming growth factor-alpha in gingival crevicular fluid from human periodontal disease. Arch Oral Biol 1999;44:535-539.
42. Gamond J, Acevedo A, Bascones A, Jorge O, Silva A. Levels of interieukin-1 beta, -8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis and the effect of periodontal treatment. J Periodontol 2000;71:1535-1545.
43. Preiss DS, Meyle J. Interleukin 1 concentration of gingival crevicular fluid. J Periodontol 1994;65:423-428.
44. Stashenko P, Dewhirst FE, Peros WJ, Kent RL, Ago JM. Synergistic interactions between interleukin 1, tumor necrosis factor and lymphotoxin in bone resorption. J Immunol 1987; 138:1464-1468.
45. Hou LT, Liu C-M, Rossomando EF. Crevicular interleukin 1 beta in moderate and severe periodontitis patients and the effects of phase 1 periodontal therapy. J Clin Periodontol 1995;22:162-167.
46. Lee H-J, Kang I-K, Chang C-P, Choi S-M. The subgingival microflora and gingival crevicular fluid cytokines in refractory periodontitis. J Clin Periodontol 1995;22:885-890.
47. Rogers MA, Figliomeni L, Baluchova K, et al. Do interleukin-1 polymorphisms predict the development of periodontitis or the success of dental implants? J Periodont Res 2002;37:37-41.
48. Geivelis M, Turner DW, Pederson ED, Lamberts BL. Measurement of interleukin-6 in gingival crevicular fluid from adults with destructive periodontal disease. J Periodontol 1993;64:980-983.
49. Guillot J, Pollack SM, Johnson RB. Gingival interleukin 6 concentrations following phase I therapy. J Periodontol 1995;66:667-672.
50. Reinhardt RA, Masada MP, Payne JB, Allison AC, DuBois LM. Gingival Fluid II-1 beta and II-6 levels in menopause. J Clin Periodontol 1994;21:22-25.
51. Offenbacher S, Soskolne WA, Collins JG. Prostaglandins and other eicasanoids in gingival crevicular fluid as markers of periodontal disease activity. In: Johnson NW, ed. Risk Markers for Oral Diseases. Cambridge: Cambridge University Press; 1991:313-337.
52. Offenbacher S, Odle BM, Braswell LD. Changes in cyclooxygenase metabolites in experimental periodontitis in Macaca mulatta. J Periodont Res 1989; 24:63-74.
53. Nakashima K, Roehrich N, Cimasoni G. Osteocalcin, prostaglandin E2 and alkaline phosphatase in gingival crevicular fluid: Their relation to periodontal status. J Clin Periodontol 1994;21:327-333.
54. Offenbacher S, Odle BM, Van Dyke TE. The use of crevicular fluid prostaglandin E2 level as a predictor of periodontal attachment loss. J Periodont Res 1986;21:101-112.
55. Shibata Y, Yamashita Y, Miyazaki H, Ueno S, Takehara T. Effective method for discriminating between oral bacterial and human alkaline phosphatase activity. Oral Microbiol Immunol 1994;9:35-39.
56. Ishikawa I, Cimasoni G. Alkaline phosphatase in human gingival fluid and its relation to periodontitis. Arch Oral Biol 1970;15:14-19.
57. Binder TA, Goodson JM, Socransky SS. Gingival fluid levels of acid and alkaline phosphatase. J Periodont Res 1987;22:14-19.
58. Chapple IL, Garner I, Saxby MS, Moscrop H, Mathews JB. Prediction and diagnosis of attachment loss by enhanced chemiluminescent assay of crevicular fluid alkaline phosphatase levels. J Clin Periodontol 1999; 26:190-198.
59. Sengupta S, Fine J, Wu-Wang C-Y. The relationship of Prostaglandins to cAMP IgG, IgM, a-2 macroglobulin in gingival crevicular fluid in chronic adult periodontitis. Arch Oral Biol 1990;35:593-596.
60. Romanelli R, Mancini S, Laschinger C, Overall CM, Sodek J, McCulloch CA. Activation of neutrophil collagenase in periodontitis. Infect Immun 1999;67:2319-2326.
61. Chen HY, Cox SW, Eley BM, Matyla P, Sorsa T. Matrix metalloproteinase-8 levels and elastase activities in gingival crevicular fluid from chronic adult periodontitis patients. J Clin Periodontol 2000;27:366-369.
62. Golub LM, Siegel K, Ramamurthy NS, Mandel ID. Some characteristics of collagenase activity in gingival crevicular fluid and its relationship to gingival disease in humans. J Dent Res 1976;55:1049-1057.
63. Overall CM, Sodek J. Initial characterization of a neutral metalloproteinase active on 3/4-collagen fragments, synthesized by ROS 17/2.8 osteoblastic cells, periodontal fibroblasts, and identified in gingival crevicular fluid. J Dent Res 1987;66:1271-1282.
64. Villela B, Cogan RB, Bartolucci AA, Birkedal-Hansen H. Collagenolytic activity in crevicular fluid from patients with chronic adult periodontitis, localized juvenile periodontitis, and gingivitis, and from healthy control subjects. J Periodont Res 1987;22:381-389.
65. Sodek J, Ferrier JM. Collagenase and collagenase inhibitor activity in crevicular fluid of patients receiving treatment for localized juvenile periodontitis. J Periodont Res 1986;21:702-715.
66. Golub LM, Lee HM, Greenwald RA, et al. A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. Inflamm Res 1997;46:310-319.
67. Sorsa T, Ingman T, Kononen M, Kottinen YT, Siirila H. Collagenase, gelatinase, and elastase activities In sulcular fluid of osseointegrated implants and natural teeth. J Clin Periodontol 1994;21:301-307.
68. Ma J, Kitti U, Husa V, et al. Collagenases in different categories of peri-implant vertical bone loss. J Dent Res 2000;79:1870-1873.
69. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107:1049-1054.
70. Bowers MR, Fisher LW, Termine JD, Somerman MJ. Connective tissue associated proteins in crevicular fluid: Potential markers for periodontal diseases. J Periodontol 1989;60:448-451.
71. Denhardt DT, Guo X. Osteopontin. A protein with diverse functions. FASEB J 1998;7:1475-1482.
72. Kido J, Nakamura T, Asahara Y, Sawa T, Kohri K, Nagata T. Osteopontin in gingival crevicular fluid. J Periodont Res 2001;36:328-333.
73. Kunimatsu K, Mataki S, Tanak H, et al. A cross sectional study on osteocalcin levels in gingival crevicular fluid from periodontal patients. J Periodontol 1993;64:865-868.
74. Giannobile WV, Lynch SE, Denmark RG, Paquette DW, Fiorellini JP, Williams RC. Crevicular fluid osteocalcin and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis. A pilot study in beagle dogs. J Clin Periodontol 1995;22:903-910.
75. Lee AJ, Walsh TE, Hodges SF, Rawlinson A. Gingival crevicular fluid osteocalcin in adult periodontitis. J Clin Periodontol 1999;26:252-256.
76. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antibacterial mechanisms. Adv Dent Res 1998; 12:12-26.
77. Talonpoika JT, Hamalainen MM. Type I carboxyterminal telopeptide in human gingival crevicular fluid in different clinical conditions and after periodontal therapy. J Clin Periodontol 1994;21:21-34.
78. Shibutani T, Murahashi Y, Tsukada E, Iwayama Y, Heersche JNM. Experimentally induced periodontitis in beagle dogs causes rapid increase in osteoclastic resorption of alveolar bone. J Periodontol 1997;68: 385-391.
79. Al-Shammari KF, Giannobile WV, Aldredge WA, et al. Effect of non-surgical periodontal therapy on C-telopeptide pyridinoline cross-links (ICTP) and interleukin-1 levels. J Periodontol 200 1;72:1045-1051.
80. Palys MD, Haffajee AD, Socransky SS, Giannobile WV. Relationship between C-telopeptide pyridinoline cross-links (ICTP) and putative periodontal pathogens in periodontitis. J Clin Periodontol 1998;25:865-871.
81. Oringer RJ, Palys MD, Iranmanesh A, et al. C-telopeptide pyridinoline cross-links (ICTP) and periodontal pathogens associated with endosseous oral implants. Clin Oral Implantol Res 1998;9:365-373.
82. Waddington RJ, Embery G. Structural characterization of human alveolar bone proteoglycans. Arch Oral Biol 1991;36:859-866.
83. Last KS, Stanbury JB, Embery G. Glycosaminoglycans in human gingival crevicular fluid as indicators of active periodontal disease. Arch Oral Biol 1985;30: 275-281.
84. Waddington RJ, Langley MS, Guida L, Iuorio G, Labelle R, Caruso F. Relationship of sulphated glycosaminoglycans in human gingival crevicular fluid with active periodontal disease. J Periodont Res 1996; 31:168-170.
85. Okazaki J, Kamada A, Matsukawa F, Sakaki T, Gonda Y. Disaccharide analyses of chondroitin sulphate in human gingival crevicular fluid using high-performance liquid chromatography. Arch Oral Biol 1995; 40:777-779.
86. Giannobile WV, Riviere GR, Gorski JP, Tira DE, Cobb CM. Glycosaminoglycans and periodontal disease: Analysis of GCF by safranin O. J Periodontol 1993;64: 186-190.
87. Samuels RHA, Pender N, Last KS. The effects of orthodontic tooth movement on the glycosaminoglycan components of gingival crevicular fluid. J Clin Periodontol 1993;20:371-377.
88. Smedberg JI, Beck CB, Embery G. Glycoaminoglycans in peri-implant sulcus fluid from implants supporting fixed or removable prostheses. Clin Oral Implantol Res 1993;4:137-143.
89. Okazaki J, Gonda Y, Kamada A, et al. Disaccharide analysis of chondroitin sulphate in peri-implant sulcus fluid from dental implants. Eur J Oral Sci 1996; 104:141-143.
90. Last KS, Cawood JI, Howel RA, Embery G. Monitoring of Tübingen endosseous dental implants by glycosaminoglycans analysis of gingival crevicular fluid. Int J Oral Maxillofac Implants 1991;6:42-49.
91. Paquette DW, Williams RC. Modulation of host inflammatory mediators as a trdatment strategy for periodontal diseases. Periodontol 2000 2001;24:239-252.
92. Verburg KM, Maziasz TJ, Weiner E, Loose L, Geis GS, Isakson PC. Cox-2-specific inhibitors: Definition of a new therapeutic concept. Am J Ther 2001;8:49-64.
93. Paquette DW, Lawrence HP, Wilder R, et al. Pharmacodynamic effects of ketoprofen on crevicular fluid prostanoids in adult periodontitis. J Clin Periodontol 2000;27:558-566.
94. Bezerra MM, de Lima V, Alencar VB, Vieira IB, Brito GA, Ribeiro RA. Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats. J Periodontol 2000;71:1009-1014.
95. Delima A, Oates T, Assuma R, et al. Soluble antagonists to interleukin- 1 (IL-1) and tumor necrosis (TNF) inhibits loss of tissue attachment in experimental periodontitis. J Clin Periodontol 2001;28:233-240.
96. Oates TW, Graves DT, Cochran DL. Clinical, radiographic and biochemical assessment of IL-I/TNF-alpha antagonist inhibition of bone loss in experimental periodontitis. J Clin Periodontol 2002;29:137-143.
97. Stronski SA, Bettschen-Camin L, Wetterwald A, Felix R, Trechsel U, Fleisch H. Bisphosphonates inhibit 1,25 dihydroxyvitamin D3-induced increase of osteocalcin in plasma of rats in vivo and in culture medium of rat calvaria in vitro. Calcif Tissue Int 1988;42:248-254.
98. Reddy MS, Weatherford TW, Smith CA, West BD, Jeffcoat MK, Jack TM. Alendronate treatment of naturally occuring periodontitis in beagle dogs. J Periodontol 1995;66:211-217.
99. Nakaya H, Osawa G, Iwasaki N, Cochran DL, Kamoi K, Oates TW. Effects of bisphosphonate on matrix metalloproteinase enzymes in human periodontal ligament cells. J Periodontol 2000;71:1158-1166.
100. Denissen H, Martinetti R, van Ungen A, van den Hoof A. Normal osteoconduction and repair in and around submerged highly bisphosphonate-complexed hydroxyapatide implants in the rat tibia. J Periodontol 2000; 71:272-278.
101. Brunsvold MA, Chaves ES, Kornman KS, Aufdemorte TB, Wood R. Effects of bisphosphonates on experimental periodontitis in monkeys. J Periodontol 1992; 63:825-830.
102. Quartuccio WM, Seedor JG, Aufdemorte TB. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodont Res 1994;29:35-39,
103. Mariotti A, Monroe PJ. Pharmacologic management of periodontal diseases using systemically administered agents. Dent Clin North Am 1998;42:245-263.
104. Jeffcoat MK, Reddy MS. Alveolar bone loss and osteoporosis: Evidence for common mode of therapy using the bisphosphonate alendronate. In: Davidovitch Z, ed. The Biologic Mechanism of Tooth Resorption and Replacement by Implants. Boston: Harvard Society for the Advancement of Orthodontics; 1996:365-373.
105. Rocha M, Nava LE, Vazquez de la Torre C, Sanchez-Marin F, Garay-Sevellia ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A random placebo-controlled trial. J Periodontol 2001;72:204-209.
106. Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy.NS. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987;66:1310-1314.
107. Vernillo AT, Rifkin ER. Effect of tetracyclines on bone metabolism. Adv Dent Res 1998;12:56-62.
108. Crout RJ, Lee HM, Schroeder K. The cyclic regimen of low-dose doxycycline for adult periodontitis: A preliminary report. J Periodontol 1996;67:506-514.
109. Ingman T, Sorsa T, Suomalainen K, et al. Tetracycline inhibition and the cellular source of collagenase in gingival crevicular fluid in different periodontal diseases. A review article. J Periodontol 1993;64:82-88.
110. Jilka RL. Cytokines, bone remodeling, and estrogen deficiency: A 1998 update. Bone 1998;23:75-81.
111. Pacifici R. Estrogen and bone loss. Adv Organ Biol 1998;5C:641-659.
112. Jeffcoat MK. Osteoporosis: A possible modifying factor in oral bone loss. Ann Periodontol 1998;3:312-321.
113. Reinhardt RA, Payne JB, Maze C, Babitt M, Nummikoski PV, Dunning D. Gingival fluid IL-1P in postmenopausal females on supportive periodontal therapy. J Clin Periodontol 1998;25:1029-1035.
114. Reinhardt RA, Payne JB, Maze C, Patil KD, Gallagher SJ, Mattson JS. Influence of estrogen and osteopenia/osteoporosis on clinical periodontitis in postmenopausal women. J Periodontol 1999;70:823-828.
115. van Steenberghe D, Jacobs R, Ghyselen J, Koninckx P. Long term bone mass evaluation of mandible and lumbar spine in a group of women receiving hormone replacement therapy. Eur J Oral Sci 1996; 104:10-16.
116. Nordyred OM, Grossi SG, Matchei EE, et al. Periodontal status of women taking postmenopausal estrogen supplementation. J Periodontol 1993;64:957-962.
117. Shiba H, Nakanishi K, Sakata M, Fujita T, Uchida Y, Kurihara H. Effects of aging on proliferative ability, and the expression of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclasto-genesis inhibitory factor) in cultures of human periodontal ligament cells. Mech Ageing Dev 2000; 117: 69-77.
118. Wada N, Maeda H, Tanabe K, et al. Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: The factor is osteoprotogerin/osteoclastogenesis inhibitory factor. J Periodont Res 2001;36:56-63.
119. Teitelbaum SL. Osteoclasts integrins, and osteoporosis. J Bone Miner Metab 2001;18:344-349.
120. Ramamurthy NS, Xu JW, Bird J, et al. Inhibition of alveolar bone loss by matrix metalloproteinase inhibitors in experimental periodontal disease. J Periodont Res 2002;37:1-7.